ES2158887T3 - Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona. - Google Patents

Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona.

Info

Publication number
ES2158887T3
ES2158887T3 ES94901556T ES94901556T ES2158887T3 ES 2158887 T3 ES2158887 T3 ES 2158887T3 ES 94901556 T ES94901556 T ES 94901556T ES 94901556 T ES94901556 T ES 94901556T ES 2158887 T3 ES2158887 T3 ES 2158887T3
Authority
ES
Spain
Prior art keywords
androst
aza
beta
butilcarbamoil
terc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94901556T
Other languages
English (en)
Inventor
Glenn J Gormley
Elizabeth Stoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2158887T3 publication Critical patent/ES2158887T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LAS 17-BETA-CARBAMOIL-4-AZA-5ALFA-ANDROST-1-2N-3-ONAS MONOSUSTITUIDAS DE FORMULA (I) DONDE R1 SE ELIGE ENTRE HIDROGENO, METILO Y ETILO Y R2 ES UN ALKILO DE CADENA RAMIFICADA O RECTA, CICLO ALKILO, ARALKILO DE 1 A 12 ATOMOS DE CARBONO, O ARILO MONOCRILICO QUE CONTIENEN 1 O MAS SUSTITUYENTES DE ALKILO INFERIOR DE 1-2 ATOMOS DE CARBONO Y/O 1 O MAS HALOGENOS, R'', R", R"'' SON HIDROGENO O METILO Y SON UTILES PARA EL TRATAMIENTO DE PROSTATITIS CRONICA.
ES94901556T 1992-12-18 1993-11-18 Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona. Expired - Lifetime ES2158887T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99298592A 1992-12-18 1992-12-18

Publications (1)

Publication Number Publication Date
ES2158887T3 true ES2158887T3 (es) 2001-09-16

Family

ID=25538974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94901556T Expired - Lifetime ES2158887T3 (es) 1992-12-18 1993-11-18 Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona.

Country Status (17)

Country Link
US (1) US5629318A (es)
EP (1) EP0674521B1 (es)
JP (1) JPH08504813A (es)
AT (1) ATE203162T1 (es)
AU (1) AU691164B2 (es)
CA (1) CA2151239A1 (es)
CZ (1) CZ285379B6 (es)
DE (1) DE69330465T2 (es)
DK (1) DK0674521T3 (es)
ES (1) ES2158887T3 (es)
FI (1) FI953002A (es)
GR (1) GR3036241T3 (es)
HU (1) HU220064B (es)
NO (1) NO308829B1 (es)
NZ (1) NZ258435A (es)
PT (1) PT674521E (es)
WO (1) WO1994014452A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059583A1 (en) * 1998-05-18 1999-11-25 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
CA2537660A1 (en) * 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
JP2007509962A (ja) * 2003-10-31 2007-04-19 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節剤としての２１−複素環−４−アザステロイド誘導体
US20080268463A1 (en) * 2007-03-07 2008-10-30 Children's Medical Center Corporation Methods for Prognosis and Diagnosis of Chronic Prostatitis/Pelvic Pain Syndrome and Interstitial Cystitis
RU2525182C1 (ru) * 2013-02-28 2014-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения больных хроническим простатитом с парциальным андрогенодефицитом
CN104161739B (zh) * 2014-08-15 2017-09-19 武汉人福药业有限责任公司 非那雄胺胶囊及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2227876A (en) * 1937-10-16 1941-01-07 Firm Of N V Organon Steroid derivatives with nuclear substituted nitrogen
US3285918A (en) * 1962-04-18 1966-11-15 Norman J Doorenbos 1', 4', 5', 6'-tetrahydropyrimidino[a-4, 3]-4-aza-5-cholestene
US3239417A (en) * 1962-12-07 1966-03-08 Smith Kline French Lab Methods and compositions for inhibiting sterol biosynthesis
US3264301A (en) * 1963-08-22 1966-08-02 Norman J Doorenbos Substituted-4-azasteroids
FR1465544A (fr) * 1965-11-29 1967-01-13 Roussel Uclaf Dérivés stéroïdes aromatiques substitués par un atome d'azote endocyclique et procédé de préparation
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US4946688A (en) * 1988-07-05 1990-08-07 Fahim Mostafa S Intraprostatic injection of zinc ions for treatment of inflammatory conditions and benign and malignant tumors of the prostate
DK627289D0 (da) * 1989-12-12 1989-12-12 Per C Oden Anvendelse af bicyclononanderivater
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
EP0663924B1 (en) * 1992-10-06 2001-02-14 Merck & Co. Inc. 17-beta-carboxanilides of 4-aza-5-alpha-androstan-3-ones as 5-alpha-reductase inhibitors

Also Published As

Publication number Publication date
WO1994014452A1 (en) 1994-07-07
DE69330465T2 (de) 2002-04-25
JPH08504813A (ja) 1996-05-28
NO952427D0 (no) 1995-06-16
PT674521E (pt) 2001-10-31
DE69330465D1 (de) 2001-08-23
HUT73231A (en) 1996-07-29
GR3036241T3 (en) 2001-10-31
AU691164B2 (en) 1998-05-14
CZ285379B6 (cs) 1999-07-14
EP0674521A4 (en) 1998-02-04
DK0674521T3 (da) 2001-09-24
FI953002A0 (fi) 1995-06-16
HU9501777D0 (en) 1995-08-28
EP0674521A1 (en) 1995-10-04
FI953002A (fi) 1995-06-16
NO952427L (no) 1995-06-16
US5629318A (en) 1997-05-13
NZ258435A (en) 1997-05-26
NO308829B1 (no) 2000-11-06
CZ157795A3 (en) 1995-11-15
AU5610594A (en) 1994-07-19
EP0674521B1 (en) 2001-07-18
HU220064B (hu) 2001-10-28
CA2151239A1 (en) 1994-07-07
ATE203162T1 (de) 2001-08-15

Similar Documents

Publication Publication Date Title
DK0687268T3 (da) Spiroazacykliske derivater som substans P-antagonister
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
FI972628A0 (fi) Uudet sulfonamidit
FI932229A0 (fi) Azabicykliska bryggderivat
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
ATE224374T1 (de) 1,2-substituierte imidazolylverbindungen zur behandlung von entzündungen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
NO970164L (no) Anvendelse av tiazol- og tiadiazolforbindelser som D3 - dopaminreseptorligander
DK0772604T3 (da) Trialzolforbindelser og deres anvendelse som dopamin-D3-ligander
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
MX9307775A (es) Nuevos antioxidantes fenolicos liquidos.
ES2158887T3 (es) Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona.
ATE148345T1 (de) Therapeutische verwendung von phosphoryl-l-serin- n-acyl-sphingosin
BR9906803A (pt) Processo para tratamento de copd
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
FI952855A (fi) Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö
ATE199547T1 (de) Arylalkoxyphenoxyimidazolinverbindungen
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 674521

Country of ref document: ES